Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance

doi:10.5498/wjp.v13.i11.937

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2677)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

WORD

HTML

1358

Figures (1-1)

185

Tables (1-7)

196

Sum=1821

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

176

Download

599

Sum=775

Nov 19, 2023 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Psychiatry. Nov 19, 2023; 13(11): 937-948
Published online Nov 19, 2023. doi: 10.5498/wjp.v13.i11.937

Table 4 Percentage of participants with extrapyramidal symptom adverse drug reactions (n = 894)

Category	n	%
All	25	2.8%
Acute dystonia	7	0.8%
Akathisia	20	2.2%
Parkinsonism	2	0.2%
Tardive dystonia	0	0.0%
Other EPS ADR	0	0.0%

EPS: Extrapyramidal symptoms; ADR: Adverse drug reactions.

Citation: Wei YM, Wang XJ, Yang XD, Wang CS, Wang LL, Xu XY, Zhao GJ, Li B, Zhu DM, Wu Q, Shen YF. Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance. World J Psychiatry 2023; 13(11): 937-948
URL: https://www.wjgnet.com/2220-3206/full/v13/i11/937.htm
DOI: https://dx.doi.org/10.5498/wjp.v13.i11.937